Marsico Capital Management LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 21.0% during the first quarter, Holdings Channel reports. The institutional investor owned 68,803 shares of the company’s stock after selling 18,292 shares during the period. Marsico Capital Management LLC’s holdings in Johnson & Johnson were worth $8,569,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the stock. Lau Associates LLC increased its stake in Johnson & Johnson by 12.8% in the first quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock worth $5,839,000 after buying an additional 5,335 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in Johnson & Johnson by 396.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 110,823 shares of the company’s stock worth $12,768,000 after buying an additional 88,510 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its stake in Johnson & Johnson by 7.3% in the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 14,124 shares of the company’s stock worth $1,627,000 after buying an additional 957 shares in the last quarter. Burke & Herbert Bank & Trust Co. increased its stake in Johnson & Johnson by 2.6% in the first quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock worth $5,895,000 after buying an additional 1,218 shares in the last quarter. Finally, Independent Advisor Alliance acquired a new stake in Johnson & Johnson during the fourth quarter worth about $4,035,000. 66.06% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson (NYSE:JNJ) traded up 0.61% during trading on Friday, reaching $133.90. 1,011,299 shares of the company were exchanged. The company has a market capitalization of $359.39 billion, a P/E ratio of 22.66 and a beta of 0.78. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The firm’s 50-day moving average is $133.18 and its 200 day moving average is $126.16.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. During the same period in the previous year, the firm earned $1.74 earnings per share. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.52%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s payout ratio is 56.76%.

COPYRIGHT VIOLATION NOTICE: “Marsico Capital Management LLC Sells 18,292 Shares of Johnson & Johnson (JNJ)” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/marsico-capital-management-llc-sells-18292-shares-of-johnson-johnson-jnj/1475303.html.

JNJ has been the subject of a number of recent research reports. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, July 5th. BidaskClub downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 1st. Vetr downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.54 price objective for the company. in a report on Monday, May 1st. Jefferies Group LLC reissued a “hold” rating and issued a $140.00 price objective on shares of Johnson & Johnson in a report on Friday, June 16th. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Friday, July 21st. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $133.72.

In related news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.